Epidermal growth factor cancer vaccine - Bioven

Drug Profile

Epidermal growth factor cancer vaccine - Bioven

Alternative Names: BV NSCLC 001; BV NSCLC 002; BVN-NSCLC-002; CimaVax EGF; EGF cancer vaccine; EGF-P64K cancer vaccine; EGF-PTI; hrEGF-rP64k-Montanide ISA 51 VG; rEGF-P64K/Montanide ISA 51 vaccine; SAI-EGF

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Center of Molecular Immunology
  • Developer Bioven; Center of Molecular Immunology
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Prostate cancer
  • Discontinued Colorectal cancer; Gastric cancer

Most Recent Events

  • 28 Jun 2016 Bioven obtains an optional US marketing rights to epidermal growth factor cancer vacine
  • 28 Jun 2016 Bioven files an IND application with the US FDA in USA for Non-small cell lung cancer before July 2016
  • 14 Jan 2016 Phase-II clinical trials in Prostate cancer in Cuba (Parenteral) (CIMAB SA pipeline; January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top